1. Home
  2. IFN vs CTNM Comparison

IFN vs CTNM Comparison

Compare IFN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo India Fund Inc. (The)

IFN

India Fund Inc. (The)

HOLD

Current Price

$12.03

Market Cap

540.6M

Sector

Finance

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$13.22

Market Cap

480.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IFN
CTNM
Founded
N/A
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
540.6M
480.5M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
IFN
CTNM
Price
$12.03
$13.22
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
145.2K
232.5K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.84
$3.35
52 Week High
$16.60
$16.33

Technical Indicators

Market Signals
Indicator
IFN
CTNM
Relative Strength Index (RSI) 51.93 52.35
Support Level $10.84 $10.17
Resistance Level $12.50 $13.26
Average True Range (ATR) 0.16 0.71
MACD 0.03 0.02
Stochastic Oscillator 24.80 68.00

Price Performance

Historical Comparison
IFN
CTNM

About IFN India Fund Inc. (The)

India Fund Inc is an asset management company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others. Geographically, all the business activity functions through the market of the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: